GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results